Search Results for keywords:"Controlled Substances"

The Department of Justice's Drug Enforcement Administration (DEA) announced a request for public comments on a new information collection plan as per the Paperwork Reduction Act. This collection aims to allow non-registrants to access the CSA Database System to verify DEA registrant status, essential for commerce activities involving controlled substances. The plan targets businesses, not-for-profit institutions, and government entities, with an estimated annual public burden of 250 hours. Public feedback is sought to ensure the necessity, accuracy, clarity, and reduced burden of the information gathering process.

Organic Consultants LLC, doing business as Cascade Chemistry, has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of certain controlled substances. Interested parties have until April 1, 2025, to submit comments or objections regarding the application or to request a hearing. Comments can be submitted electronically through the Federal eRulemaking Portal. The company intends to produce small amounts of these substances for internal use or to sell as analytical reference standard materials, with no other activities authorized for these drug codes.

The Drug Enforcement Administration (DEA) has announced that Cosmic Light LLC, located in Boulder, Colorado, has applied to become a registered bulk manufacturer of marihuana, classified as a Schedule I controlled substance. This registration would allow them to produce bulk materials needed to develop pharmaceutical products for research purposes. Interested parties have until April 30, 2021, to submit comments or objections regarding this application. The DEA will review this application following its established regulations to ensure compliance and prevent misuse.

The National Center for Natural Products Research has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of specific controlled substances. Specifically, they intend to manufacture these substances for product development and reference standards. The controlled substances include drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), which will be isolated from Marihuana Extract (7350), but no cultivation of marihuana is authorized. Interested parties have until February 11, 2025, to submit comments or request a hearing on this application.

Veranova, L.P. has applied to become a registered bulk manufacturer of specific controlled substances. The application has been submitted to the Drug Enforcement Administration (DEA) to support their manufacturing and analytical testing needs. Public comments or objections regarding this application can be submitted electronically through the Federal eRulemaking Portal until March 25, 2025. Individuals may also request a hearing about the application by the same date.

The Drug Enforcement Administration (DEA) has received an application from AJC Industries, Inc. to become a registered bulk manufacturer of marihuana, a Schedule I controlled substance, for scientific and medical research. This notice allows current registered manufacturers and other applicants to submit comments or objections by April 26, 2021. The DEA will evaluate the application to ensure compliance with legal and regulatory standards and to prevent misuse. Interested parties need to reference Docket No. DEA-797 when submitting their feedback to the DEA's office in Springfield, Virginia.

Navinta LLC has applied to the Drug Enforcement Administration to become a registered bulk manufacturer of certain controlled substances. This registration is part of the process to gain approval for manufacturing these substances for validation purposes, which is a step required by the Food Administration before the substances can be distributed to their customers. The public, including current manufacturers of these substances, can submit comments or objections electronically by February 4, 2025. Comments should be submitted through the Federal eRulemaking Portal to ensure they are properly received.

The Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have decided to delay the start date for two rules about using telemedicine to prescribe certain medications to December 31, 2025. These rules include the "Expansion of Buprenorphine Treatment via Telemedicine Encounter," which allows practitioners to prescribe medications for opioid use disorder, and "Continuity of Care via Telemedicine for Veterans Affairs Patients," which permits Veterans Affairs practitioners to prescribe controlled substances via telemedicine under specific conditions. The delay grants additional time to address any questions or issues and follows public feedback, with some comments favoring an immediate start and others requesting a postponement.

Noramco has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances, including Poppy Straw Concentrate and an intermediate form of Tapentadol. They plan to use these substances to manufacture other drugs for their customers. As part of their application, they also intend to import synthetic cannabidiol and synthetic Tetrahydrocannabinol, while noting that they will not import finished drugs for commercial sale. The public can submit comments or request a hearing on this application by January 6, 2025.